Shanghai Medicilon Inc. (SHA:688202)

Market Cap	8.26B
Revenue (ttm)	1.06B
Net Income (ttm)	-273.51M
Shares Out	131.55M
EPS (ttm)	-2.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,352,640
Average Volume	5,217,360
Open	63.97
Previous Close	63.60
Day's Range	62.39 - 65.30
52-Week Range	25.10 - 84.70
Beta	0.86
RSI	44.56
Earnings Date	Oct 31, 2025

About Shanghai Medicilon

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates through Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development services; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation servic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2,349
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688202

Financial Performance

In 2024, Shanghai Medicilon's revenue was 1.04 billion, a decrease of -24.01% compared to the previous year's 1.37 billion. Losses were -330.85 million, 896.2% more than in 2023.